Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Q2 Revenues Flat, Losses Narrow

NEW YORK, July 29 - Sequenom reported flat revenues for the second quarter today, amid narrowed net losses.

The San Diego company had revenues of $7.7 million for the quarter, compared to revenues of $7.7 million for the same period last year.

 

R&D expenses came to $6.5 million, compared to $8.1 million for the year-ago quarter.

 

The company's net loss narrowed to $9.3 million, from $15 million in the second quarter of 2002.

 

As of June 30, Sequenom had $82.9 million in cash, cash equivalents, short-term investments, and restricted cash.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.